A Stronger Path Forward for Infection Control and Antimicrobial Resistance: Learning From COVID-19
FIVE YEARS AGO, the world was thrust into an unprecedented health crisis with the COVID-19 pandemic. At the time, hospitals, governments, and health organizations scrambled to respond, focusing massive attention and resources on curbing the viral threat.
Remembering Professor Virginia “Ginny” Greiman (SED’70, LAW’03)
Virginia “Ginny” Greiman (SED’70, LAW’03), a former deputy chief counsel of Boston’s Big Dig project, an expert in international development who consulted with global institutions such as the World Bank, and a longtime lecturer at Boston University School of Law, died on November 15 after a battle with cancer.
CARB-X Receives Global Funding in Fight Against Antimicrobial Resistance
Recently, the CARB-X received significant funding from three governments to continue their work on breakthrough therapeutics, vaccines, and diagnostics.
Recognizing Excellence in Faculty
When Boston University School of Law Professor Kevin Outterson was named the Austin B. Fletcher Professor of Law last fall in recognition of his research, teaching, and scholarship, he assumed a title that dates back nearly a century.
Can we Prevent Antibiotic Resistance?
Antibiotics have saved countless lives since they were introduced in the 1940s, curing infections and making procedures like chemotherapy and surgeries safer. But as bacteria evolve, many have become resistant to antibiotics.
CARB-X Funds Sutrovax to Develop a New Vaccine to Prevent Group A Streptococcal Infections
Vaccines are essential in the global fight against drug-resistant bacteria .
CARB-X funds Vaxxilon AG to Develop a New Vaccine to Prevent Superbug Infections
The vaccine aims to prevent deadly hospital-acquired respiratory, urinary-tract, and other infections that kill thousands of patients each year.
CARB-X Funds BB100 to Treat Hyper-Virulent Multi-Drug-Resistant E. coli Infections
New alternative-to-antibiotic treatment in development to fight infections associated with E. coli superbug.
CARB-X Funds Debiopharm to Develop a New Class of Antibiotics to Treat Hospital-Acquired Pneumonia
Debiopharm’s new Debio 1454 is the company’s second project to be awarded CARB-X support
CARB-X Expands its Global Accelerator Network
Life sciences organizations from around the world brought together to support the development of antibiotics, rapid diagnostics, vaccines and other life-saving products to combat drug-resistant superbugs.